8-K: Brainstorm Cell Therapeutics Faces Nasdaq Delisting Threat After Falling Below Minimum Market Value

Brainstorm Cell Therapeutics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting its listing status at risk.

Summary

• Brainstorm Cell Therapeutics received a notice from Nasdaq on July 18, 2024, stating that its Market Value of Listed Securities (MVLS) fell below the required $35 million minimum.
• The company's MVLS was below the minimum from June 2, 2024, to July 17, 2024.
• Brainstorm has until January 14, 2025, to regain compliance by having its MVLS close at or above $35 million for at least ten consecutive business days.
• If compliance is not achieved by the deadline, Nasdaq may issue a delisting notice, which the company can appeal.
• There is no guarantee that an appeal would be successful, and the company is actively monitoring its MVLS and taking measures to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern for investors.

Positives

• The company has been given a 180-day grace period to regain compliance with Nasdaq listing requirements.
• The company's stock continues to trade on the Nasdaq Capital Market under the symbol BCLI during the compliance period.
• The company intends to take all reasonable measures to regain compliance.

Negatives

• The company's Market Value of Listed Securities (MVLS) fell below the required $35 million minimum.
• The company faces the risk of delisting from the Nasdaq Capital Market if it fails to regain compliance by January 14, 2025.
• There is no guarantee that the company will be able to regain or maintain compliance with the Nasdaq listing standards.

Risks

• The company may be delisted from the Nasdaq Capital Market if it does not regain compliance with the MVLS requirement by January 14, 2025.
• There is no assurance that the company will be able to successfully appeal a delisting determination.
• The company's stock price may be negatively impacted by the delisting notice and the uncertainty surrounding its future listing status.

Future Outlook

The company intends to actively monitor its MVLS and take all reasonable measures to regain compliance with the Nasdaq listing requirements, but there is no guarantee of success.

Management Comments

• The company intends to actively monitor the Companys MVLS between now and the Compliance Date and will take all reasonable measures available to the Company to regain compliance with the MVLS Requirement.
• While the Company is exercising diligent efforts to maintain the listing of its common stock on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with the applicable continued listing standards set forth in the Nasdaq Listing Rules.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining their listing status, particularly when market conditions are volatile. It is not uncommon for companies to receive delisting notices, and the ability to regain compliance often depends on market sentiment and the company's ability to raise capital or improve its financial performance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those with volatile stock prices and limited revenue.
• Companies like Brainstorm often rely on clinical trial progress and regulatory approvals to drive their stock price, making them susceptible to market fluctuations.
• The $35 million MVLS requirement is a standard benchmark for Nasdaq Capital Market listings, and failure to meet this threshold is a common reason for delisting notices.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• The company will actively monitor its MVLS.
• The company will take all reasonable measures to regain compliance with the MVLS requirement.
• The company may appeal any delisting determination if it fails to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, MVLS, market value, compliance, listing, BCLI, Brainstorm Cell Therapeutics